Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-12-10
2002-08-06
Cochrane Carlson, Karen (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S014800, C514S825000, C514S885000, C424S810000, C424S443000, C424S430000, C424S282100, C530S350000, C530S387100, C530S389500, C435S006120, C435S842000
Reexamination Certificate
active
06429189
ABSTRACT:
FIELD OF INVENTION
This invention relates to the composition of chemodenervating agents used for the treatment of diseases. The invention offers an improvement on the prior art by eliminating the muscle-weakening side effect of prior-art chemodenervating agents. This is achieved by eliminating the neurotoxin component of the chemodenervating agent.
BACKGROUND OF THE INVENTION
Migraine and tension headaches are a major cause of loss of productivity for those afflicted, usually due to pain and associated systemic symptoms. The syndrome of migraine and other essential headaches is characterized by severe throbbing headaches often made worse by physical activity and associated with aversion to light and sound. The syndrome often, but not always, includes nausea and/or sometimes vomiting as major components. The pain is often unilateral or localized to a portion of the head. The condition is episodic in nature, with episodes typically lasting 4-72 hours.
Tension headache is the most common type of essential headache and is characterized by head pain not associated with any structural lesions, often not associated with nausea, and occurring more frequently and less episodically than migraine headache.
Recently
botulinum
toxin injections within the head and neck region have been advocated as a method to treat migraine headache, tension headache, and myofascial pain, both acutely and for prophylaxis. Efficacy for both myofascial pain and migraine headaches has been shown in double-blind placebo-controlled trials. However, the mechanism of action has not been clearly explained, as
botulinum
toxin has been thought to exert its beneficial effects for most indications by causing decreased muscle tone and contractility. The major limiting factor involved in injecting
botulinum
toxin is the muscle-weakening effect. For instance, ptosis (drooping of the upper eyelid) is the major side effect caused by the injection of neurotoxin for the treatment of human headache disorders. This results from the neuromuscular paralytic effects of the neurotoxin component of the
botulinum
toxin molecule.
Recently, the present inventor has shown
botulinum
toxin to have anti-inflammatory components, both in vivo in man and in animal experiments. This unique property has not been previously appreciated or defined and in fact may explain the mechanism of action by which
botulinum
toxin exerts its beneficial effects in essential headache disorders (migraine and tension headaches) as well as in other medical conditions. Evidence that
botulinum
toxin acts on the inflammatory response associated with essential headaches can be categorized into clinical observations and animal experiments as disclosed herein.
BRIEF SUMMARY OF THE INVENTION
A limiting property of
botulinum
toxin for the treatment of pain or inflammatory disease relates to its weakening effect on muscle tissue caused by blocking acetylcholine release by its neurotoxin component. The utility of the invention described herein is based upon a compositional change to the
botulinum
exotoxin proteins used in medical practice that eliminates neurotoxin activity, while maintaining a biological activity that is capable of suppressing pain and inflammation. Such compositional improvement allows the exotoxin protein to be used without the attendant risk of inducing muscle atrophy and weakness, while retaining a biological effect useful for the clinical relief-of pain and discomfort.
REFERENCES:
patent: 5053005 (1991-10-01), Borodic
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5562907 (1996-10-01), Arnon
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5714468 (1998-02-01), Binder
patent: 5837265 (1998-11-01), Montal et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
Ohishi et al., Infect. Immun., vol. 31, No. 3, pp.890-895, 1981.*
Acquadro M et al. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 3/94;80(3): 705-6.
Amann R et al. Intraplantar injection of nerve growth factor into the rat hind paw: local edema and effects on thermal nociceptive threshold. Pain, 1995; 64: 323-329.
Ashikaga T et al. Multiple daily insulin injections in the treatment of diabetic retinopathy. The Job study revisited. Diabetes, 5/78; 27(5): 592-6.
Bischoff SC et al. Effect of Nerve Growth Factor on the Release of Inflammatory Medators by Mature Human Basophils. Blood, May 15, 1992; 79(10): 2663-2669.
Borodic G et al. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 12/92; 90(6): 972-7.
Borodic G Myasthenic crisis after botulinum toxin. Lancet, Dec. 5, 1998; 352(9143): 1832.
Borodic G et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1/96; 46(1): 26-9.
Borodic G et al. Antibodies to botulinum toxin. Neurology 1/95; 45(1): 204.
Borodic G Therapeutic botulinum toxin. Lancet Nov. 12, 1994; 344(8933): 1370.
Borodic G et al. New concepts in botulinum toxin therapy. Drug Saf 9/94; 11(3): 145-52.
Borodic G et al. Antibodies to bowline toxin. Ophthalmology 7/94; 11(3): 1158-9.
Borodic G et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injection. Movement Disorders 1994; 9(1): 31-39.
Borodic G et al. Botulinum A toxin for treatment of aberrant facial nerve rgeneration. Plast Reconstr Surg 5/93; 91(6): 1042-5.
Borodic G et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 1993; 9(3): 182-90.
Borodic G et al. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 6/92; 12(2):121-7.
Borodic G et al. Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck 1-2/92; 14(1): 33-7.
Borodic G et al. Treatment of spasticity with botulinum toxin. Ann Neurol 1/92; 31(1): 113.
Borodic G Botulinum A toxin for (expressionisic) ptosis overcorrection after frontalis sling. Ophthal Plast Reconstr Surg 1992; 8(2): 137-42.
Borodic G et al. Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plast Reconstr Surg 2/91; 87(2): 285-9.
Borodic G et al. Innervation zone of orbicularis oculi muscles and implications fo rbotulinum A toxin therapy. Ophthal Plast Reconstr Surg 1991; 7(1): 54-60.
Borodic G et al. Botulinum A toxin for the treatment of spasmodic torticolilis dysphagia and rgional toxin spread. Head Neck 9-10/90; 12(5): 392-9.
Borodic G et al. Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast Reconstr Surg 3/89; 83(3): 546-54.
Borodic G et al. Dermis fat graft in eviscerated sockets. Opthal Plast Reconst Surg 1989; 5(2): 144-9.
Borodic G et al. Immunoglobulin deposition in localized conjuctival amyloidosis. Am J Ophthalmol 11/84; 98(5): 617-22.
Borodic G et al. Peripapillary subretinal neovascularization and serous macular detachment. Association with congeital optic nerve pits. Arch Opthalmol 2/84; 102(2): 229-31.
Borodic G et al. Photophobia and benign essential blepharospasm.
Borodic G et al. Therapeutic botulinum toxin; histologic effects and diffusion properties. DasGupta BR, ed. Botulinum and Tetanus Neurotoxins. Plenum Press, New York, 1993 623-45.
Borodic G. Botulinum toxin: issue and applications. Otolaryngology Head Neck Surg 1999; 219-25.
Borodic G et al. Pharmacology and histology of the therapeutic application of boulinum toxin.
Bottinger H et al. Inhibition of histamine release from rat mast cells by botulinum C2 toxin. Int Arch Allergy Appl Immunol 187; 84(4): 380-4.
Brooks A et al. Reactive oxygen species generation and histamine release by activated mast cells: modulation by nitric oxide synthase inhibition. Br J. Pharmacol 1999; 128:585-90.
Calderone J et al. Intraocular pathology of trisomy 18 (Edward's syndrome): report if a case and review of the literature. Br J Ophthalmol 3/83; 67(3): 162-9.
Chen X et al. NOS Inhibitor
Botulinum Toxin Research Associates, Inc.
Carlson Karen Cochrane
Milbank Tweed Hadley & McCloy LLP
Robinson Hope A.
LandOfFree
Cytotoxin (non-neurotoxin) for the treatment of human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxin (non-neurotoxin) for the treatment of human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxin (non-neurotoxin) for the treatment of human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2956553